IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
Yiming Aongke-B (01541) announced that the Phase II randomized and placebo-controlled trial of IMM0306 for the treatment of systemic lupus erythematosus (SLE) has successfully administered the first dose to a patient. It is expected to recruit approximately 90 patients, who will be randomly assigned in a 1:1:1 ratio to three treatment groups to receive treatment with IMM0306 (doses of 1.2 mg/kg and 1.6 mg/kg) or placebo.
IMMUNEONCO-B(01541) issued an announcement that the phase II randomized placebo-controlled trial of IMM0306 for the treatment of systemic lupus erythematosus (SLE) has successfully dosed the first patient. It is expected to recruit approximately 90 patients, who will be randomly assigned in a 1:1:1 ratio to three treatment groups, receiving treatment with IMM0306 (doses of 1.2 mg/kg and 1.6 mg/kg) or placebo.
Related Articles
The controlling shareholder of General Elevator (300931.SZ) and some directors and senior executives are planning to reduce their combined stake by no more than 3.21%.
DYNAGREEN ENV (01330) will distribute a final dividend of HK$0.22 per share on July 8th.
HUANXI MEDIA (01003) plans to issue 731 million subscription shares to PHANCY (06682) and enter into a strategic cooperation and joint venture framework agreement.
The controlling shareholder of General Elevator (300931.SZ) and some directors and senior executives are planning to reduce their combined stake by no more than 3.21%.
DYNAGREEN ENV (01330) will distribute a final dividend of HK$0.22 per share on July 8th.
HUANXI MEDIA (01003) plans to issue 731 million subscription shares to PHANCY (06682) and enter into a strategic cooperation and joint venture framework agreement.
